SHORT COMMUNICATION
Development of hammerhead ribozymes targeting miR-21
 
More details
Hide details
 
Publication date: 2015-12-21
 
 
BioTechnologia 2014;95(4):267-271
 
ABSTRACT
The object of the invention are hammerhead ribozymes directed against the sequence of miR-21 and /or miR-21 precursors, having the ability to specifically cleave miR-21 and /or miR- 21 precursors, and wherein they have acatalytic core with a sequence as shown in SEQ ID No 1. The invention also relates to a composition comprising such ribozymes, a therapeutic agent comprising them, a use of such ribozymes and a method of selective cleavage of miR-21 and /or 1 miR-21 precursors employing such ribozymes.
REFERENCES (8)
1.
Campbell J.M., Bacon T.A., Wickstrom E. (1990) Oligodeoxynucleotide phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. J. Biochem. Biophys. Meth. 20: 259-267.
 
2.
Ferre-D’Amare A.R., Scott W.G. (2010) Small self-cleaving ribozymes. Cold Spring Harb. Perspect. Biol. 2: a003574.
 
3.
Gumireddy K., Young D.D., Xiong X., Hogenesch J.B., Huang Q., Deiters A. (2008) Small-molecule inhibitors of microRNA miR-21 function. Angew. Chem. Int. Ed. Engl. 47:7482-7484.
 
4.
Kurreck J. (2003) Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 270: 1628-1644.
 
5.
Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Eng. J. Med. 352: 987-996.
 
6.
Sun L.Q., Cairns M.J., Saravolac E.G., Baker A. et al. (2000) Catalytic nucleic acids: form lab to applications. Pharmacol. Rev. 52: 325-347.
 
7.
Suryawanshi H., Scaria V., Maiti S. (2010) Modulation of microRNA function by synthetic ribozymes. Mol. Biosyst. 6: 1807-1809.
 
8.
Westphal M., Hilt D.C., Bortey E., Delavault P., Olivares R., Warnke P.C., Whittle I.R., Jaakelamen J., Ram Z. (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neurooncol 5: 79-88.
 
eISSN:2353-9461
ISSN:0860-7796
Journals System - logo
Scroll to top